BARDA bets $483M on Moderna’s Covid-19 vaccine as the biotech plots ultra-fast PhIII, recruiting 150 staffers to scale up 24/7
BARDA has agreed to gamble up to $483 million on Moderna’s clinical-stage vaccine to guard against SARS-CoV-2 — a move that will fund development through a hoped-for BLA filing for accelerated approval while opening the door to a pivotal study as early as the fall of this year. And the biotech is launching a recruitment campaign to hire 150 staffers to ramp up a 24/7 schedule on manufacturing designed to quickly scale up to tens of millions of doses.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 93,000+ biopharma pros reading Endpoints daily — and it's free.